About veracyte inc - VCYT
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
VCYT At a Glance
Veracyte, Inc.
6000 Shoreline Court
South San Francisco, California 94080
| Phone | 1-650-243-6300 | Revenue | 517.15M | |
| Industry | Medical Specialties | Net Income | 66.35M | |
| Sector | Health Technology | 2025 Sales Growth | 16.013% | |
| Fiscal Year-end | 12 / 2026 | Employees | 755 | |
| View SEC Filings |
VCYT Valuation
| P/E Current | 39.162 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 51.123 |
| Price to Sales Ratio | 6.559 |
| Price to Book Ratio | 2.551 |
| Price to Cash Flow Ratio | 24.89 |
| Enterprise Value to EBITDA | 26.253 |
| Enterprise Value to Sales | 5.838 |
| Total Debt to Enterprise Value | 0.013 |
VCYT Efficiency
| Revenue/Employee | 684,960.265 |
| Income Per Employee | 87,884.768 |
| Receivables Turnover | 11.58 |
| Total Asset Turnover | 0.373 |
VCYT Liquidity
| Current Ratio | 8.148 |
| Quick Ratio | 7.805 |
| Cash Ratio | 6.889 |
VCYT Profitability
| Gross Margin | 68.573 |
| Operating Margin | 18.095 |
| Pretax Margin | 13.188 |
| Net Margin | 12.831 |
| Return on Assets | 4.789 |
| Return on Equity | 5.339 |
| Return on Total Capital | 4.918 |
| Return on Invested Capital | 5.175 |
VCYT Capital Structure
| Total Debt to Total Equity | 3.028 |
| Total Debt to Total Capital | 2.939 |
| Total Debt to Total Assets | 2.759 |
| Long-Term Debt to Equity | 2.719 |
| Long-Term Debt to Total Capital | 2.639 |